Plasmanate Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to expansion of surgical procedures requiring volume replacement, availability of plasma fractionation technologies, rising trauma and burn treatment cases, adoption of albumin-based therapies, growth in hospital critical care units.

The growth in the forecast period can be attributed to increasing demand for safer plasma-derived products, rising investments in plasma collection infrastructure, expansion of emergency and trauma care services, growing focus on protein-based therapeutics, advancements in plasma processing technologies. Major trends in the forecast period include increasing use of plasma protein volume expanders, rising demand for blood-derived therapeutics, growing emphasis on safe and pasteurized plasma products, expansion of critical care applications, enhanced focus on supply chain traceability.

The increasing incidence of trauma cases is expected to support the expansion of the plasmanate market in the coming years. Trauma cases involve severe physical or psychological injuries caused by external forces or distressing events and often require immediate medical intervention, surgical procedures, rehabilitation, and psychological care for recovery. The rise in trauma cases is attributed to higher accident rates, urbanization that increases exposure to hazardous environments, and lifestyle changes such as greater risk-taking behavior and substance abuse. Patients with trauma may experience hypovolemic shock due to substantial blood loss, making plasma transfusion essential for restoring blood volume and maintaining stable blood pressure. For instance, in 2025, according to the Wisconsin Department of Health Services (DHS), a US-based state health agency, trauma cases in Wisconsin increased by approximately 5.6% between 2023 and 2024. Therefore, the growing incidence of trauma cases is contributing to the growth of the plasmanate market.

The rising prevalence of chronic illnesses is expected to drive the expansion of the plasmanate market in the years ahead. Chronic illnesses are long-term health conditions that typically last for a year or longer and often require continuous medical care or limit daily activities. The increasing burden of chronic illnesses is driven by greater exposure to risk factors such as obesity, high blood pressure, and unhealthy lifestyles, along with aging populations and environmental factors that contribute to non-communicable diseases. Plasmanate is used in the management of chronic conditions to restore plasma volume and address hypoproteinemia in diseases such as liver disorders, severe burns, and nephrotic syndrome. For example, in 2025, according to the Northern Arizona Medical Group, a US-based healthcare provider, nearly three-quarters of the global population is projected to live with at least one chronic illness, with prevalence continuing to rise significantly. In the United States, in 2023, about 76.4% of adults reported having at least one chronic condition, while 51.4% had two or more. Therefore, the increasing prevalence of chronic illnesses is supporting the growth of the plasmanate market.

The growing prevalence of autoimmune diseases is anticipated to propel the growth of the plasmanate market going forward. Autoimmune diseases develop when the immune system mistakenly attacks the body’s own healthy cells, tissues, and organs, identifying them as foreign. The rise in autoimmune conditions is linked to factors such as improved awareness and diagnosis, genetic susceptibility, and environmental influences including pollution, dietary habits, and lifestyle changes. Plasmanate is used in autoimmune conditions to restore plasma volume and stabilize hemodynamic function, helping support patients during immune-related crises. For instance, in July 2024, according to the National Health Service (NHS) England, a UK-based government health authority, multiple sclerosis affects more than 150,000 people in the UK, including over 120,000 individuals in England, and is more common among women. Approximately 135 new cases are diagnosed each week, underscoring the substantial impact of the disease. Therefore, the increasing prevalence of autoimmune diseases is driving the growth of the plasmanate market.

Major companies operating in the plasmanate market are Grifols Therapeutics LLC.

North America was the largest region in the plasmanate market in 2025. The regions covered in the plasmanate market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the plasmanate market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are influencing the plasmanate market by increasing costs of imported plasma collection equipment, fractionation systems, sterile packaging materials, and cold-chain logistics essential for plasma protein production. Hospitals and clinical research laboratories in North America and Europe are most affected due to dependence on imported processing technologies, while Asia-Pacific faces cost pressures in plasma sourcing and distribution. These tariffs are increasing procurement expenses and affecting product availability. At the same time, they are encouraging domestic plasma fractionation, regional plasma collection initiatives, and localized production of plasma-derived therapeutics.

The plasmanate market research report is one of a series of new reports that provides plasmanate market statistics, including plasmanate industry global market size, regional shares, competitors with a plasmanate market share, detailed plasmanate market segments, market trends and opportunities, and any further data you may need to thrive in the plasmanate industry. This plasmanate market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Plasmanate is a plasma protein fraction obtained from human blood and is mainly composed of albumin, serving as a volume expander in clinical practice. It is commonly administered to manage hypovolemia, or reduced blood volume, resulting from surgery, trauma, or burn injuries. The product undergoes pasteurization to minimize the risk of viral transmission and enhance patient safety.

The primary formulations of Plasmanate include liquid and lyophilized forms. Liquid formulations consist of Plasmanate in a ready-to-use liquid state that can be directly administered to patients to replenish fluids and proteins. These formulations are frequently used in emergency and hospital environments for prompt and effective therapy. The liquid form enables rapid infusion and delivers immediate therapeutic benefits. Clinical uses of Plasmanate include hypovolemia, burns, shock, hypoproteinemia, and surgical interventions. It is distributed through multiple channels, including online pharmacies and wholesale distributors, and is extensively used by hospitals and clinical research laboratories.

The plasmanate market consists of sales of plasmanate 5% infusion, and plasmanate 5% injection 250ml. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.